CVE-2019-6986

CVE-2019-6986 is a high-severity vulnerability in Duraspace Vitro with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-77.

Key facts

Description

SPARQL Injection in VIVO Vitro v1.10.0 allows a remote attacker to execute arbitrary SPARQL via the uri parameter, leading to a regular expression denial of service (ReDoS), as demonstrated by crafted use of FILTER%20regex in a /individual?uri= request.

Frequently asked questions

What is CVE-2019-6986?
SPARQL Injection in VIVO Vitro v1.10.0 allows a remote attacker to execute arbitrary SPARQL via the uri parameter, leading to a regular expression denial of service (ReDoS), as demonstrated by crafted use of FILTER%20regex in a /individual?uri= request.
How severe is CVE-2019-6986?
CVE-2019-6986 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity none, and availability high.
Is CVE-2019-6986 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 3% (86th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2019-6986?
CVE-2019-6986 affects Duraspace Vitro. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2019-6986?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2019-6986 published?
CVE-2019-6986 was published on 2019-01-28 and last updated on 2026-06-17.

References

Affected products (1)

Other CWE-77 (Command Injection) vulnerabilities

Browse all CWE-77 (Command Injection) vulnerabilities →